secwatch.observer — SEC 8-K summary
======================================

Issuer:     SPRUCE BIOSCIENCES, INC. (SPRB)
CIK:        0001683553
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0000950170-24-058635
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spruce Biosciences Q1 net loss $11.6M; cash $81.2M; CAHmelia-204 data expected Q3 2024
--------------------------------------------------------------------------------

- Cash and cash equivalents $81.2M as of March 31, 2024; expected to fund operations through end of 2025.
- Net loss of $11.6M vs $12.8M in Q1 2023; R&D expenses $10.3M (down from $11.7M).
- Collaboration revenue of $2.0M from Kaken Pharmaceutical agreement.
- CAHmelia-203 analyses show higher GC dose and drug compliance correlate with larger A4 reductions.
- Topline data from CAHmelia-204 (adult CAH) and interim dose-ranging from CAHptain-205 (pediatric) expected Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1683553/000095017024058635/0000950170-24-058635-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1683553/000095017024058635/sprb-20240513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-058635

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer